ELVN

SEC source: 0001209191-23-013522 · doc4.xml · derivative · entry 4

Heyman Richard A. · CIK 0001584759 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,657

Underlying: Common Stock · 20,657 shares

Expires 2032-08-12

F5 · price: In connection with the Merger, each Enliven stock option that was outstanding immediately prior to the effective time of the Merger was assumed by Imara and became an option to acquire, on the same terms and conditions as were applicable to such Enliven stock option immediately prior to the effective time of the Merger, a number of shares of Imara common stock equal to the number of shares of Enliven common stock subject to the unexercised portion of the Enliven stock option immediately prior to the effective time of the Merger, multiplied by the exchange ratio (rounded down to the nearest whole share number), with an exercise price per share for the options equal to the exercise price per share of such Enliven stock option immediately prior to the effective time of the Merger divided by the exchange ratio (rounded up to the nearest whole cent).

F4 · derivative.exercise_date: The option is subject to an early exercise provision and the shares underlying the option vest in 48 equal monthly installments beginning on January 14, 2021.

SEC source: 0001209191-23-013522 · doc4.xml · nonDerivative · entry 3

Heyman Richard A. · CIK 0001584759 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 31,172

F1 · price: Pursuant to the Agreement and Plan of Merger, dated as of October 13, 2022 (the "Merger Agreement"), by and among Imara Inc. ("Imara"), Enliven Therapeutics, Inc., ("Enliven") and Iguana Merger Sub, Inc., a wholly owned subsidiary of the Issuer (the "Merger Sub"), which provided for the merger of Merger Sub with and into Enliven, with Enliven surviving the merger as a wholly-owned subsidiary of Imara (the "Merger"). At the effective time of the Merger, each share of Enliven common stock was converted into the right to receive a number of shares of Imara common stock equal to an exchange ratio of approximately 0.2951 shares of Imara common stock for each share of Enliven common stock. After completion of the Merger, the combined company will be renamed "Enliven Therapeutics, Inc." and the common stock of the combined company will trade on The Nasdaq Stock Market under the symbol "ELVN."

F3 · ownership.nature: The shares held of record by RAHD Capital LLC for which the reporting person serves as a managing member.

SEC source: 0001209191-23-013522 · doc4.xml · nonDerivative · entry 2

Heyman Richard A. · CIK 0001584759 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 37,407

F1 · price: Pursuant to the Agreement and Plan of Merger, dated as of October 13, 2022 (the "Merger Agreement"), by and among Imara Inc. ("Imara"), Enliven Therapeutics, Inc., ("Enliven") and Iguana Merger Sub, Inc., a wholly owned subsidiary of the Issuer (the "Merger Sub"), which provided for the merger of Merger Sub with and into Enliven, with Enliven surviving the merger as a wholly-owned subsidiary of Imara (the "Merger"). At the effective time of the Merger, each share of Enliven common stock was converted into the right to receive a number of shares of Imara common stock equal to an exchange ratio of approximately 0.2951 shares of Imara common stock for each share of Enliven common stock. After completion of the Merger, the combined company will be renamed "Enliven Therapeutics, Inc." and the common stock of the combined company will trade on The Nasdaq Stock Market under the symbol "ELVN."

F2 · ownership.nature: The shares held of record by the Richard A. Heyman and Anne E. Daigle Trust, dated November 1, 2016 for which the reporting person serves as trustee.

SEC source: 0001209191-23-013522 · doc4.xml · nonDerivative · entry 1

Heyman Richard A. · CIK 0001584759 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 149,820

F1 · price: Pursuant to the Agreement and Plan of Merger, dated as of October 13, 2022 (the "Merger Agreement"), by and among Imara Inc. ("Imara"), Enliven Therapeutics, Inc., ("Enliven") and Iguana Merger Sub, Inc., a wholly owned subsidiary of the Issuer (the "Merger Sub"), which provided for the merger of Merger Sub with and into Enliven, with Enliven surviving the merger as a wholly-owned subsidiary of Imara (the "Merger"). At the effective time of the Merger, each share of Enliven common stock was converted into the right to receive a number of shares of Imara common stock equal to an exchange ratio of approximately 0.2951 shares of Imara common stock for each share of Enliven common stock. After completion of the Merger, the combined company will be renamed "Enliven Therapeutics, Inc." and the common stock of the combined company will trade on The Nasdaq Stock Market under the symbol "ELVN."

SEC source: 0001209191-23-013526 · doc4.xml · nonDerivative · entry 2

Schwab Andrew J. · CIK 0001598549 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 960,383

F1 · price: Pursuant to the Agreement and Plan of Merger, dated as of October 13, 2022 (the "Merger Agreement"), by and among Imara Inc. ("Imara"), Enliven Therapeutics, Inc., ("Enliven") and Iguana Merger Sub, Inc., a wholly owned subsidiary of the Issuer (the "Merger Sub"), provided for the merger of Merger Sub with and into Enliven, with Enliven surviving the merger as a wholly-owned subsidiary of the Imara (the "Merger"). At the effective time of the Merger, each share of Enliven common stock was converted into the right to receive a number of shares of Imara common stock equal to an exchange ratio of approximately 0.2951 shares of Imara common stock for each share of Enliven common stock. After completion of the Merger, the combined company will be renamed "Enliven Therapeutics, Inc." and the common stock of the combined company will trade on The Nasdaq Stock Market under the symbol "ELVN."

F3 · ownership.nature: The shares held of record by 5AM Ventures Opportunities I, L.P. (5AM Opportunities). 5AM Opportunities I (GP), LLC (5AM Opportunities GP) is the general partner of 5AM Opportunities and may be deemed to have sole investment and voting power over the shares held by 5AM Opportunities. As a managing member 5AM Opportunities GP, the reporting person may be deemed to share voting and dispositive power over the shares held of record by 5AM Opportunities but disclaims beneficial ownership of the securities held of record by 5AM Opportunities except to the extent of his individual pecuniary interest therein.

SEC source: 0001209191-23-013526 · doc4.xml · nonDerivative · entry 1

Schwab Andrew J. · CIK 0001598549 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 4,838,092

F1 · price: Pursuant to the Agreement and Plan of Merger, dated as of October 13, 2022 (the "Merger Agreement"), by and among Imara Inc. ("Imara"), Enliven Therapeutics, Inc., ("Enliven") and Iguana Merger Sub, Inc., a wholly owned subsidiary of the Issuer (the "Merger Sub"), provided for the merger of Merger Sub with and into Enliven, with Enliven surviving the merger as a wholly-owned subsidiary of the Imara (the "Merger"). At the effective time of the Merger, each share of Enliven common stock was converted into the right to receive a number of shares of Imara common stock equal to an exchange ratio of approximately 0.2951 shares of Imara common stock for each share of Enliven common stock. After completion of the Merger, the combined company will be renamed "Enliven Therapeutics, Inc." and the common stock of the combined company will trade on The Nasdaq Stock Market under the symbol "ELVN."

F2 · ownership.nature: The shares held of record by 5AM Ventures VI, L.P. (5AM VI). 5AM Partners VI, LLC (5AM Partners) is the general partner of 5AM VI and may be deemed to have sole investment and voting power over the shares held by 5AM VI. As a managing member of 5AM Partners, the reporting person may be deemed to share voting and dispositive power over the shares held of record by 5AM VI but disclaims beneficial ownership of the securities held of record by 5AM VI except to the extent of his individual pecuniary interest therein.

SEC source: 0001209191-23-013517 · doc4.xml · nonDerivative · entry 2

Gupta Rishi · CIK 0001537370 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 288,114

F1 · price: Pursuant to the Agreement and Plan of Merger, dated as of October 13, 2022 (the "Merger Agreement"), by and among Imara Inc. ("Imara"), Enliven Therapeutics, Inc., ("Enliven") and Iguana Merger Sub, Inc., a wholly owned subsidiary of the Issuer (the "Merger Sub"), which provided for the merger of Merger Sub with and into Enliven, with Enliven surviving the merger as a wholly-owned subsidiary of Imara (the "Merger"). At the effective time of the Merger, each share of Enliven common stock was converted into the right to receive a number of shares of Imara common stock equal to an exchange ratio of approximately 0.2951 shares of Imara common stock for each share of Enliven common stock. After completion of the Merger, the combined company will be renamed "Enliven Therapeutics, Inc." and the common stock of the combined company will trade on The Nasdaq Stock Market under the symbol "ELVN."

F3 · ownership.nature: Each of the Reporting Person, OrbiMed Advisors, GP VII, and Genesis GP disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that the Reporting Person is a beneficial owner of such securities for purpose of Section 16 of the Exchange Act, or for any other purpose.

F4 · ownership.nature: The shares are held of record by OrbiMed Genesis Master Fund, L.P. ("Genesis"). OrbiMed Genesis GP LLC ("Genesis GP") is the general partner of Genesis. OrbiMed Advisors is the managing member of Genesis GP. By virtue of such relationships, Genesis GP and OrbiMed Advisors may be deemed to have voting and investment power over the securities held by Genesis and may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by Genesis.

SEC source: 0001209191-23-013517 · doc4.xml · nonDerivative · entry 1

Gupta Rishi · CIK 0001537370 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 7,611,458

F1 · price: Pursuant to the Agreement and Plan of Merger, dated as of October 13, 2022 (the "Merger Agreement"), by and among Imara Inc. ("Imara"), Enliven Therapeutics, Inc., ("Enliven") and Iguana Merger Sub, Inc., a wholly owned subsidiary of the Issuer (the "Merger Sub"), which provided for the merger of Merger Sub with and into Enliven, with Enliven surviving the merger as a wholly-owned subsidiary of Imara (the "Merger"). At the effective time of the Merger, each share of Enliven common stock was converted into the right to receive a number of shares of Imara common stock equal to an exchange ratio of approximately 0.2951 shares of Imara common stock for each share of Enliven common stock. After completion of the Merger, the combined company will be renamed "Enliven Therapeutics, Inc." and the common stock of the combined company will trade on The Nasdaq Stock Market under the symbol "ELVN."

F2 · ownership.nature: The shares are held of record by OrbiMed Private Investments VII, LP ("OPI VII"). OrbiMed Capital GP VII LLC ("GP VII") is the general partner of OPI VII and OrbiMed Advisors LLC ("OrbiMed Advisors"), a registered investment adviser under the Investment Advisers Act, is the managing member of GP VII. The Reporting Person is an employee of OrbiMed Advisors. By virtue of such relationships, GP VII and OrbiMed Advisors may be deemed to have voting and investment power over the securities held by OPI VII and may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L.Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VII.

F3 · ownership.nature: Each of the Reporting Person, OrbiMed Advisors, GP VII, and Genesis GP disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that the Reporting Person is a beneficial owner of such securities for purpose of Section 16 of the Exchange Act, or for any other purpose.

SEC source: 0001209191-23-013515 · doc4.xml · derivative · entry 2

Bauer Jake · CIK 0001654909 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,706

Underlying: Common Stock · 17,706 shares

Expires 2032-08-12

F2 · derivative.exercise_date: Shares subject to the option vest in 24 equal monthly installments beginning on September 24, 2022.

SEC source: 0001209191-23-013515 · doc4.xml · nonDerivative · entry 1

Bauer Jake · CIK 0001654909 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 87,372

F1 · price: Pursuant to the Agreement and Plan of Merger, dated as of October 13, 2022 (the "Merger Agreement"), by and among Imara Inc. ("Imara"), Enliven Therapeutics, Inc., ("Enliven") and Iguana Merger Sub, Inc., a wholly owned subsidiary of the Issuer (the "Merger Sub"), provided for the merger of Merger Sub with and into Enliven, with Enliven surviving the merger as a wholly-owned subsidiary of the Imara (the "Merger"). At the effective time of the Merger, each share of Enliven common stock was converted into the right to receive a number of shares of Imara common stock equal to an exchange ratio of approximately 0.2951 shares of Imara common stock for each share of Enliven common stock. After completion of the Merger, the combined company will be renamed "Enliven Therapeutics, Inc." and the common stock of the combined company will trade on The Nasdaq Stock Market under the symbol "ELVN."

SEC source: 0001209191-23-013496 · doc4.xml · derivative · entry 5

Patel Anish · CIK 0001967163 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 75,620

Underlying: Common Stock · 75,620 shares

Expires 2031-03-24

F4 · price: In connection with the Merger, each Enliven stock option that was outstanding immediately prior to the effective time of the Merger was assumed by Imara and became an option to acquire, on the same terms and conditions as were applicable to such Enliven stock option immediately prior to the effective time of the Merger, a number of shares of Imara common stock equal to the number of shares of Enliven common stock subject to the unexercised portion of the Enliven stock option immediately prior to the effective time of the Merger, multiplied by the exchange ratio (rounded down to the nearest whole share number), with an exercise price per share for the options equal to the exercise price per share of such Enliven stock option immediately prior to the effective time of the Merger divided by the exchange ratio (rounded up to the nearest whole cent).

F6 · derivative.exercise_date: Shares subject to the option vest in 48 equal monthly installments beginning on August 14, 2021.

SEC source: 0001209191-23-013496 · doc4.xml · derivative · entry 4

Patel Anish · CIK 0001967163 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,827

Underlying: Common Stock · 2,827 shares

Expires 2031-03-24

F4 · price: In connection with the Merger, each Enliven stock option that was outstanding immediately prior to the effective time of the Merger was assumed by Imara and became an option to acquire, on the same terms and conditions as were applicable to such Enliven stock option immediately prior to the effective time of the Merger, a number of shares of Imara common stock equal to the number of shares of Enliven common stock subject to the unexercised portion of the Enliven stock option immediately prior to the effective time of the Merger, multiplied by the exchange ratio (rounded down to the nearest whole share number), with an exercise price per share for the options equal to the exercise price per share of such Enliven stock option immediately prior to the effective time of the Merger divided by the exchange ratio (rounded up to the nearest whole cent).

F5 · derivative.exercise_date: Shares subject to the option vest in 24 equal monthly installments beginning on September 9, 2022.

SEC source: 0001209191-23-013496 · doc4.xml · derivative · entry 3

Patel Anish · CIK 0001967163 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,767

Underlying: Common Stock · 10,767 shares

Expires 2030-06-15

F4 · price: In connection with the Merger, each Enliven stock option that was outstanding immediately prior to the effective time of the Merger was assumed by Imara and became an option to acquire, on the same terms and conditions as were applicable to such Enliven stock option immediately prior to the effective time of the Merger, a number of shares of Imara common stock equal to the number of shares of Enliven common stock subject to the unexercised portion of the Enliven stock option immediately prior to the effective time of the Merger, multiplied by the exchange ratio (rounded down to the nearest whole share number), with an exercise price per share for the options equal to the exercise price per share of such Enliven stock option immediately prior to the effective time of the Merger divided by the exchange ratio (rounded up to the nearest whole cent).

F3 · derivative.exercise_date: Shares subject to the option vest in 48 equal monthly installments beginning on May 3, 2020.

SEC source: 0001209191-23-013496 · doc4.xml · nonDerivative · entry 2

Patel Anish · CIK 0001967163 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 394,027

F1 · price: Pursuant to the Agreement and Plan of Merger, dated as of October 13, 2022 (the "Merger Agreement"), by and among Imara Inc. ("Imara"), Enliven Therapeutics, Inc., ("Enliven") and Iguana Merger Sub, Inc., a wholly owned subsidiary of the Issuer (the "Merger Sub"), which provided for the merger of Merger Sub with and into Enliven, with Enliven surviving the merger as a wholly-owned subsidiary of Imara (the "Merger"). At the effective time of the Merger, each share of Enliven common stock was converted into the right to receive a number of shares of Imara common stock equal to an exchange ratio of approximately 0.2951 shares of Imara common stock for each share of Enliven common stock. After completion of the Merger, the combined company will be renamed "Enliven Therapeutics, Inc." and the common stock of the combined company will trade on The Nasdaq Stock Market under the symbol "ELVN."

F2 · ownership.nature: The shares are held by The Patel / Dong Family Trust Dated August 24 2017 for which the reporting person serves as trustee.

SEC source: 0001209191-23-013496 · doc4.xml · nonDerivative · entry 1

Patel Anish · CIK 0001967163 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 36,722

F1 · price: Pursuant to the Agreement and Plan of Merger, dated as of October 13, 2022 (the "Merger Agreement"), by and among Imara Inc. ("Imara"), Enliven Therapeutics, Inc., ("Enliven") and Iguana Merger Sub, Inc., a wholly owned subsidiary of the Issuer (the "Merger Sub"), which provided for the merger of Merger Sub with and into Enliven, with Enliven surviving the merger as a wholly-owned subsidiary of Imara (the "Merger"). At the effective time of the Merger, each share of Enliven common stock was converted into the right to receive a number of shares of Imara common stock equal to an exchange ratio of approximately 0.2951 shares of Imara common stock for each share of Enliven common stock. After completion of the Merger, the combined company will be renamed "Enliven Therapeutics, Inc." and the common stock of the combined company will trade on The Nasdaq Stock Market under the symbol "ELVN."

SEC source: 0001209191-23-013494 · doc4.xml · derivative · entry 1

Hohl Benjamin · CIK 0001882764 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 262,120

Underlying: Common Stock · 262,120 shares

Expires 2031-08-02

F2 · price: Pursuant to the Agreement and Plan of Merger, dated as of October 13, 2022 (the "Merger Agreement"), by and among Imara Inc. ("Imara"), Enliven Therapeutics, Inc., ("Enliven") and Iguana Merger Sub, Inc., a wholly owned subsidiary of the Issuer (the "Merger Sub"), each Enliven stock option that was outstanding immediately prior to the effective time of the Merger was assumed by Imara and became an option to acquire, on the same terms and conditions as were applicable to such Enliven stock option immediately prior to the effective time of the Merger, a number of shares of Imara common stock equal to the number of shares of Enliven common stock subject to the unexercised portion of the Enliven stock option immediately prior to the effective time of the Merger, multiplied by the exchange ratio of approximately 0.2951 shares of Imara common stock for each share of Enliven common stock (rounded down to the nearest whole share number), (footnote continued in footnote (3))

F3 · price: (continued from footnote (2)): with an exercise price per share for the options equal to the exercise price per share of such Enliven stock option immediately prior to the effective time of the Merger divided by the exchange ratio (rounded up to the nearest whole cent).

F1 · derivative.exercise_date: One-fourth of the shares subject to the option vested on August 2, 2022, and the remainder vest in 36 equal monthly installments thereafter.

SEC source: 0001209191-23-013492 · doc4.xml · derivative · entry 1

Collins Helen Louise · CIK 0001701247 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 287,084

Underlying: Common Stock · 287,084 shares

Expires 2031-06-17

F2 · price: Pursuant to the Agreement and Plan of Merger, dated as of October 13, 2022 (the "Merger Agreement"), by and among Imara Inc. ("Imara"), Enliven Therapeutics, Inc., ("Enliven") and Iguana Merger Sub, Inc., a wholly owned subsidiary of the Issuer (the "Merger Sub"), each Enliven stock option that was outstanding immediately prior to the effective time of the Merger was assumed by Imara and became an option to acquire, on the same terms and conditions as were applicable to such Enliven stock option immediately prior to the effective time of the Merger, a number of shares of Imara common stock equal to the number of shares of Enliven common stock subject to the unexercised portion of the Enliven stock option immediately prior to the effective time of the Merger, multiplied by the exchange ratio of approximately 0.2951 shares of Imara common stock for each share of Enliven common stock (rounded down to the nearest whole share number), (footnote continued in footnote (3))

F3 · price: (continued from footnote (2)): with an exercise price per share for the options equal to the exercise price per share of such Enliven stock option immediately prior to the effective time of the Merger divided by the exchange ratio (rounded up to the nearest whole cent).

F1 · derivative.exercise_date: One-fourth of the shares subject to the option vested on June 17, 2022, and the remainder vest in 36 equal monthly installments thereafter.

SEC source: 0001493152-23-006118 · ownership.xml · nonDerivative · entry 2

COMMODORE CAPITAL LP · CIK 0001831942 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By Commodore Capital Master LP

Disclosed balance after: 1,448,640

F3 · kind: On February 23, 2023, IMARA Inc. ("IMARA") completed a merger with Enliven Therapeutics, Inc. ("Legacy Enliven"), with Legacy Enliven surviving the merger as a direct wholly owned subsidiary of IMARA (the "Merger"). Prior to the Merger, the Reporting Person was a shareholder of both IMARA and Legacy Enliven. At the effective time of the Merger, the Reporting Person's 2,473,327 shares in Legacy Enliven converted into 729,891 shares of IMARA's Common Stock. In connection with the Merger, the Reporting Person also received a dividend of one Contingent Value Right ("CVR") for or each outstanding share of IMARA's Common Stock held on February 22, 2023. Accordingly, the Reporting Person received 2,872,513 CVRs, each representing the right to receive contingent payments upon the occurrence of certain events, as set forth in the Contingent Value Rights Agreement. As a result of the Merger, the Reporting Person is no longer a 10% owner of the Issuer as of the date of this Form 4.

F3 · shares: On February 23, 2023, IMARA Inc. ("IMARA") completed a merger with Enliven Therapeutics, Inc. ("Legacy Enliven"), with Legacy Enliven surviving the merger as a direct wholly owned subsidiary of IMARA (the "Merger"). Prior to the Merger, the Reporting Person was a shareholder of both IMARA and Legacy Enliven. At the effective time of the Merger, the Reporting Person's 2,473,327 shares in Legacy Enliven converted into 729,891 shares of IMARA's Common Stock. In connection with the Merger, the Reporting Person also received a dividend of one Contingent Value Right ("CVR") for or each outstanding share of IMARA's Common Stock held on February 22, 2023. Accordingly, the Reporting Person received 2,872,513 CVRs, each representing the right to receive contingent payments upon the occurrence of certain events, as set forth in the Contingent Value Rights Agreement. As a result of the Merger, the Reporting Person is no longer a 10% owner of the Issuer as of the date of this Form 4.

F3 · price: On February 23, 2023, IMARA Inc. ("IMARA") completed a merger with Enliven Therapeutics, Inc. ("Legacy Enliven"), with Legacy Enliven surviving the merger as a direct wholly owned subsidiary of IMARA (the "Merger"). Prior to the Merger, the Reporting Person was a shareholder of both IMARA and Legacy Enliven. At the effective time of the Merger, the Reporting Person's 2,473,327 shares in Legacy Enliven converted into 729,891 shares of IMARA's Common Stock. In connection with the Merger, the Reporting Person also received a dividend of one Contingent Value Right ("CVR") for or each outstanding share of IMARA's Common Stock held on February 22, 2023. Accordingly, the Reporting Person received 2,872,513 CVRs, each representing the right to receive contingent payments upon the occurrence of certain events, as set forth in the Contingent Value Rights Agreement. As a result of the Merger, the Reporting Person is no longer a 10% owner of the Issuer as of the date of this Form 4.

F2 · ownership.nature: The shares are held directly by Commodore Capital Master LP ("Commodore Master"). Commodore Capital LP ("Commodore Capital") is the investment manager to Commodore Master. Michael Kramarz and Robert Egen Atkinson are the managing partners of Commodore Capital and exercise investment and dispositive power over the securities held by Commodore Master. Each of Commodore Capital, Dr. Kramarz and Dr. Atkinson disclaim beneficial ownership of such securities, except to the extent of their pecuniary interest therein. This report shall not be deemed an admission that Commodore Capital, Commodore Master, Dr. Kramarz and Dr. Atkinson or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.

SEC source: 0001493152-23-006118 · ownership.xml · nonDerivative · entry 1

COMMODORE CAPITAL LP · CIK 0001831942 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By Commodore Capital Master LP

Disclosed balance after: 718,749

F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $20.72 to $25.28 per share, inclusive, prior to the consummation of the Merger (as defined below). The Reporting Person undertakes to provide to Issuer any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein.

F2 · ownership.nature: The shares are held directly by Commodore Capital Master LP ("Commodore Master"). Commodore Capital LP ("Commodore Capital") is the investment manager to Commodore Master. Michael Kramarz and Robert Egen Atkinson are the managing partners of Commodore Capital and exercise investment and dispositive power over the securities held by Commodore Master. Each of Commodore Capital, Dr. Kramarz and Dr. Atkinson disclaim beneficial ownership of such securities, except to the extent of their pecuniary interest therein. This report shall not be deemed an admission that Commodore Capital, Commodore Master, Dr. Kramarz and Dr. Atkinson or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.

SEC source: 0001104659-23-026032 · tm237990-1_4.xml · nonDerivative · entry 1

RA CAPITAL MANAGEMENT, L.P. · CIK 0001346824 · Former 10% owner

RA Capital Healthcare Fund LP · CIK 0001315082 · Former 10% owner

Kolchinsky Peter · CIK 0001384859 · Former 10% owner

Shah Rajeev M. · CIK 0001619841 · Former 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 2,122,465

F1 · price: Received in exchange for 3,905,254 shares of common stock of Enliven Therapeutics, Inc. ("Enliven") pursuant to an Agreement and Plan of Merger by and among Enliven, the Issuer, and Iguana Merger Sub, Inc., a wholly-owned subsidiary of the Issuer ("Merger Sub"), as amended (the "Merger Agreement"). Under the terms of the Merger Agreement, on February 23, 2023, Merger Sub merged with and into Enliven (the "Merger"), with Enliven surviving the Merger as a wholly-owned subsidiary of the Issuer and the surviving corporation of the Merger. Upon the closing of the Merger, each share of Enliven common stock was converted into the right to receive 0.295105222522519 shares of the Issuer's common stock. Subsequent to the Merger, the name of the Issuer was changed from Imara, Inc. to Enliven Therapeutics, Inc.

F2 · balance_after: On February 23, 2023, the Issuer effected a 1-for-4 reverse stock split of its common stock (the "Reverse Stock Split"). The number of shares reported on this Form 4 has been adjusted to reflect the Reverse Stock Split.

F3 · balance_after: Held directly by RA Capital Healthcare Fund, L.P. (the "Fund").

F3 · ownership.nature: Held directly by RA Capital Healthcare Fund, L.P. (the "Fund").

F4 · ownership.nature: RA Capital Management, L.P. (the "Adviser") is the investment manager for the Fund. The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.

SEC source: 0001209191-23-023664 · doc4.xml · derivative · entry 1

Derynck Mika K · CIK 0001865125 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 27,567

Underlying: Common Stock · 27,567 shares

Expires 2033-02-23

F1 · derivative.exercise_date: 1/36th of the shares subject to the option will vest on March 23, 2023 and each month thereafter, subject to the Reporting Person continuing as a service provider through each such date.

SEC source: 0001209191-23-023661 · doc4.xml · derivative · entry 1

Ballal Rahul D. · CIK 0001805097 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 27,567

Underlying: Common Stock · 27,567 shares

Expires 2033-02-23

F1 · derivative.exercise_date: 1/36th of the shares subject to the option will vest on March 23, 2023 and each month thereafter, subject to the Reporting Person continuing as a service provider through each such date.

SEC source: 0001209191-23-023669 · doc4.xml · derivative · entry 1

Schwab Andrew J. · CIK 0001598549 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 27,567

Underlying: Common Stock · 27,567 shares

Expires 2033-02-23

F1 · derivative.exercise_date: 1/36th of the shares subject to the option will vest on March 23, 2023 and each month thereafter, subject to the Reporting Person continuing as a service provider through each such date.

SEC source: 0001209191-23-023668 · doc4.xml · derivative · entry 1

Phillips Andrew John · CIK 0001921956 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 27,567

Underlying: Common Stock · 27,567 shares

Expires 2033-02-23

F1 · derivative.exercise_date: 1/36th of the shares subject to the option will vest on March 23, 2023 and each month thereafter, subject to the Reporting Person continuing as a service provider through each such date.

SEC source: 0001209191-23-023666 · doc4.xml · derivative · entry 1

Heyman Richard A. · CIK 0001584759 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 34,458

Underlying: Common Stock · 34,458 shares

Expires 2033-02-23

F1 · derivative.exercise_date: 1/36th of the shares subject to the option will vest on March 23, 2023 and each month thereafter, subject to the Reporting Person continuing as a service provider through each such date.

SEC source: 0001209191-23-023665 · doc4.xml · derivative · entry 1

Gupta Rishi · CIK 0001537370 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 27,567

Underlying: Common Stock · 27,567 shares

Expires 2033-02-23

F1 · derivative.exercise_date: 1/36th of the shares subject to the option will vest on March 23, 2023 and each month thereafter, subject to the Reporting Person continuing as a service provider through each such date.

SEC source: 0001209191-23-023662 · doc4.xml · derivative · entry 1

Bauer Jake · CIK 0001654909 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 27,567

Underlying: Common Stock · 27,567 shares

Expires 2033-02-23

F1 · derivative.exercise_date: 1/36th of the shares subject to the option will vest on March 23, 2023 and each month thereafter, subject to the Reporting Person continuing as a service provider through each such date.

SEC source: 0001209191-23-012015 · doc4.xml · nonDerivative · entry 1

Ballal Rahul D. · CIK 0001805097 · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 87,835

F1 · kind: The sales reported on this Form 4 represent shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units.

SEC source: 0001209191-23-012016 · doc4.xml · nonDerivative · entry 1

GRAY MICHAEL · CIK 0001271411 · CFO & COO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 27,610

F1 · kind: The sales reported on this Form 4 represent shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units.

SEC source: 0001493152-23-005870 · ownership.xml · nonDerivative · entry 2

COMMODORE CAPITAL LP · CIK 0001831942 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By Commodore Capital Master LP

Disclosed balance after: 2,872,513

F3 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.45 to $5.64 per share, inclusive. The Reporting Person undertakes to provide to Issuer any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein.

F2 · ownership.nature: The shares are held directly by Commodore Capital Master LP ("Commodore Master"). Commodore Capital LP ("Commodore Capital") is the investment manager to Commodore Master. Michael Kramarz and Robert Egen Atkinson are the managing partners of Commodore Capital and exercise investment and dispositive power over the securities held by Commodore Master. Each of Commodore Capital, Dr. Kramarz and Dr. Atkinson disclaim beneficial ownership of such securities, except to the extent of their pecuniary interest therein. This report shall not be deemed an admission that Commodore Capital, Commodore Master, Dr. Kramarz and Dr. Atkinson or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.

SEC source: 0001493152-23-005870 · ownership.xml · nonDerivative · entry 1

COMMODORE CAPITAL LP · CIK 0001831942 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By Commodore Capital Master LP

Disclosed balance after: 2,848,948

F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.18 to $5.37 per share, inclusive. The Reporting Person undertakes to provide to Issuer any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein.

F2 · ownership.nature: The shares are held directly by Commodore Capital Master LP ("Commodore Master"). Commodore Capital LP ("Commodore Capital") is the investment manager to Commodore Master. Michael Kramarz and Robert Egen Atkinson are the managing partners of Commodore Capital and exercise investment and dispositive power over the securities held by Commodore Master. Each of Commodore Capital, Dr. Kramarz and Dr. Atkinson disclaim beneficial ownership of such securities, except to the extent of their pecuniary interest therein. This report shall not be deemed an admission that Commodore Capital, Commodore Master, Dr. Kramarz and Dr. Atkinson or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.

SEC source: 0001209191-23-005993 · doc4.xml · nonDerivative · entry 1

Ballal Rahul D. · CIK 0001805097 · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 120,696

F1 · kind: The sales reported on this Form 4 represent shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units.

SEC source: 0001209191-23-005996 · doc4.xml · nonDerivative · entry 1

GRAY MICHAEL · CIK 0001271411 · CFO & COO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 37,466

F1 · kind: The sales reported on this Form 4 represent shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units.

SEC source: 0001567619-23-000371 · doc1.xml · nonDerivative · entry 1

Leonard Braden Michael · CIK 0001373603 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · Holding of BML Investment Partners, L.P.

Disclosed balance after: 1,767,774

F1 · ownership.direct: BML Capital Management, LLC ("BML Capital") serves as the general partner of BML Investment Partners, L.P., a Delaware limited partnership (the "Fund"), which is the direct owner of the subject shares. Mr. Leonard is the managing member of BML Capital, and exercises investment and voting control over the subject shares. Accordingly, shares owned directly by the Fund may be regarded as being beneficially owned by Mr. Leonard. Notwithstanding, Mr. Leonard disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein.

F1 · ownership.nature: BML Capital Management, LLC ("BML Capital") serves as the general partner of BML Investment Partners, L.P., a Delaware limited partnership (the "Fund"), which is the direct owner of the subject shares. Mr. Leonard is the managing member of BML Capital, and exercises investment and voting control over the subject shares. Accordingly, shares owned directly by the Fund may be regarded as being beneficially owned by Mr. Leonard. Notwithstanding, Mr. Leonard disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein.

SEC source: 0001567619-23-000570 · doc1.xml · nonDerivative · entry 1

Leonard Braden Michael · CIK 0001373603 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · Holding of BML Investment Partners, L.P.

Disclosed balance after: 1,767,774

F2 · date: This form was filed to correct the transaction date to 1/3/2023.

F1 · ownership.direct: BML Capital Management, LLC ("BML Capital") serves as the general partner of BML Investment Partners, L.P., a Delaware limited partnership (the "Fund"), which is the direct owner of the subject shares. Mr. Leonard is the managing member of BML Capital, and exercises investment and voting control over the subject shares. Accordingly, shares owned directly by the Fund may be regarded as being beneficially owned by Mr. Leonard. Notwithstanding, Mr. Leonard disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein.

F1 · ownership.nature: BML Capital Management, LLC ("BML Capital") serves as the general partner of BML Investment Partners, L.P., a Delaware limited partnership (the "Fund"), which is the direct owner of the subject shares. Mr. Leonard is the managing member of BML Capital, and exercises investment and voting control over the subject shares. Accordingly, shares owned directly by the Fund may be regarded as being beneficially owned by Mr. Leonard. Notwithstanding, Mr. Leonard disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein.

SEC source: 0001104659-23-001465 · tm232283-1_4seq1.xml · nonDerivative · entry 1

RA CAPITAL MANAGEMENT, L.P. · CIK 0001346824 · 10% owner

RA Capital Healthcare Fund LP · CIK 0001315082 · 10% owner

Kolchinsky Peter · CIK 0001384859 · 10% owner

Shah Rajeev M. · CIK 0001619841 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 3,880,021

F1 · price: This transaction was executed in multiple trades at prices ranging from $3.67 to $4.00; the price reported above reflects the weighted average purchase price. The reporting person hereby undertakes, upon request, to provide full information to the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer regarding the number of shares and prices at which these transactions, and all other transactions reported in this Form 4, were effected.

F2 · balance_after: Held directly by RA Capital Healthcare Fund, L.P. (the "Fund").

F1 · ownership.nature: This transaction was executed in multiple trades at prices ranging from $3.67 to $4.00; the price reported above reflects the weighted average purchase price. The reporting person hereby undertakes, upon request, to provide full information to the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer regarding the number of shares and prices at which these transactions, and all other transactions reported in this Form 4, were effected.

F3 · ownership.nature: RA Capital Management, L.P. (the "Adviser") is the investment manager for the Fund. The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.

SEC source: 0001567619-22-022154 · doc1.xml · nonDerivative · entry 1

Leonard Braden Michael · CIK 0001373603 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 230,000

F2 · price: The shares were sold in multiple transactions at $4.04. Full information regarding the number of shares sold can be furnished to the SEC staff upon request.

SEC source: 0001567619-22-022103 · doc1.xml · nonDerivative · entry 2

Leonard Braden Michael · CIK 0001373603 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 250,000

F2 · price: The shares were sold in multiple transactions at $4.06. Full information regarding the number of shares sold can be furnished to the SEC staff upon request.

SEC source: 0001567619-22-022103 · doc1.xml · nonDerivative · entry 1

Leonard Braden Michael · CIK 0001373603 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 269,843

SEC source: 0001567619-22-022014 · doc1.xml · nonDerivative · entry 2

Leonard Braden Michael · CIK 0001373603 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 270,000

F2 · price: The shares were sold in multiple transactions at $4.06. Full information regarding the number of shares sold can be furnished to the SEC staff upon request.

SEC source: 0001567619-22-022014 · doc1.xml · nonDerivative · entry 1

Leonard Braden Michael · CIK 0001373603 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 318,922

SEC source: 0001104659-22-126294 · tm2232492-1_4seq1.xml · nonDerivative · entry 2

RA CAPITAL MANAGEMENT, L.P. · CIK 0001346824 · 10% owner

RA Capital Healthcare Fund LP · CIK 0001315082 · 10% owner

Kolchinsky Peter · CIK 0001384859 · 10% owner

Shah Rajeev M. · CIK 0001619841 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 3,250,724

F2 · price: This transaction was executed in multiple trades at prices ranging from $3.83 to $3.95; the price reported above reflects the weighted average purchase price. The reporting person hereby undertakes, upon request, to provide full information to the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer regarding the number of shares and prices at which these transactions, and all other transactions reported in this Form 4, were effected.

F3 · balance_after: Held directly by the Fund.

F3 · ownership.nature: Held directly by the Fund.

F4 · ownership.nature: RA Capital Management, L.P. (the "Adviser") is the investment manager for the Fund. The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.

SEC source: 0001104659-22-126294 · tm2232492-1_4seq1.xml · nonDerivative · entry 1

RA CAPITAL MANAGEMENT, L.P. · CIK 0001346824 · 10% owner

RA Capital Healthcare Fund LP · CIK 0001315082 · 10% owner

Kolchinsky Peter · CIK 0001384859 · 10% owner

Shah Rajeev M. · CIK 0001619841 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 3,231,425

F1 · balance_after: Held directly by RA Capital Healthcare Fund, L.P. (the "Fund").

F1 · ownership.nature: Held directly by RA Capital Healthcare Fund, L.P. (the "Fund").

F4 · ownership.nature: RA Capital Management, L.P. (the "Adviser") is the investment manager for the Fund. The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.

SEC source: 0001104659-22-110940 · tm2228817-2_4seq1.xml · nonDerivative · entry 3

RA CAPITAL MANAGEMENT, L.P. · CIK 0001346824 · 10% owner

RA Capital Healthcare Fund LP · CIK 0001315082 · 10% owner

Kolchinsky Peter · CIK 0001384859 · 10% owner

Shah Rajeev M. · CIK 0001619841 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 3,220,825

F6 · price: This transaction was executed in multiple trades at prices ranging from $3.86 to $3.94; the price reported above reflects the weighted average purchase price

F5 · balance_after: These securities include 3,220,825 held directly by the Fund.

F5 · ownership.nature: These securities include 3,220,825 held directly by the Fund.

F7 · ownership.nature: RA Capital Management, L.P. (the "Adviser") is the investment manager for the Fund. The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.

SEC source: 0001104659-22-110940 · tm2228817-2_4seq1.xml · nonDerivative · entry 2

RA CAPITAL MANAGEMENT, L.P. · CIK 0001346824 · 10% owner

RA Capital Healthcare Fund LP · CIK 0001315082 · 10% owner

Kolchinsky Peter · CIK 0001384859 · 10% owner

Shah Rajeev M. · CIK 0001619841 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 3,194,365

F4 · price: This transaction was executed in multiple trades at prices ranging from $3.87 to $3.95; the price reported above reflects the weighted average purchase price.

F3 · balance_after: These securities include 3,194,365 held directly by the Fund.

F3 · ownership.nature: These securities include 3,194,365 held directly by the Fund.

F7 · ownership.nature: RA Capital Management, L.P. (the "Adviser") is the investment manager for the Fund. The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.

SEC source: 0001104659-22-110940 · tm2228817-2_4seq1.xml · nonDerivative · entry 1

RA CAPITAL MANAGEMENT, L.P. · CIK 0001346824 · 10% owner

RA Capital Healthcare Fund LP · CIK 0001315082 · 10% owner

Kolchinsky Peter · CIK 0001384859 · 10% owner

Shah Rajeev M. · CIK 0001619841 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 3,146,265

F2 · price: This transaction was executed in multiple trades at the price of $3.95. The reporting person hereby undertakes to provide full information regarding the number of shares and prices at which these transactions, and all other transactions reported in this Form 4, were effected upon request to the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.

F1 · balance_after: These securities include 3,146,265 held directly by RA Capital Healthcare Fund, L.P. (the "Fund").

F1 · ownership.nature: These securities include 3,146,265 held directly by RA Capital Healthcare Fund, L.P. (the "Fund").

F7 · ownership.nature: RA Capital Management, L.P. (the "Adviser") is the investment manager for the Fund. The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.

SEC source: 0001104659-22-110004 · tm2228584-2_4seq1.xml · nonDerivative · entry 3

RA CAPITAL MANAGEMENT, L.P. · CIK 0001346824 · 10% owner

RA Capital Healthcare Fund LP · CIK 0001315082 · 10% owner

Kolchinsky Peter · CIK 0001384859 · 10% owner

Shah Rajeev M. · CIK 0001619841 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 3,134,923

F6 · price: This transaction was executed in multiple trades at prices ranging from $3.80 to $3.95; the price reported above reflects the weighted average purchase price.

F5 · balance_after: These securities include 3,134,923 held directly by the Fund.

F5 · ownership.nature: These securities include 3,134,923 held directly by the Fund.

F7 · ownership.nature: RA Capital Management, L.P. (the "Adviser") is the investment manager for the Fund. The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.

SEC source: 0001104659-22-110004 · tm2228584-2_4seq1.xml · nonDerivative · entry 2

RA CAPITAL MANAGEMENT, L.P. · CIK 0001346824 · 10% owner

RA Capital Healthcare Fund LP · CIK 0001315082 · 10% owner

Kolchinsky Peter · CIK 0001384859 · 10% owner

Shah Rajeev M. · CIK 0001619841 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 3,009,197

F4 · price: This transaction was executed in multiple trades at prices ranging from $3.45 to $3.95; the price reported above reflects the weighted average purchase price.

F3 · balance_after: These securities include 3,009,197 held directly by the Fund.

F3 · ownership.nature: These securities include 3,009,197 held directly by the Fund.

F7 · ownership.nature: RA Capital Management, L.P. (the "Adviser") is the investment manager for the Fund. The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.

SEC source: 0001104659-22-110004 · tm2228584-2_4seq1.xml · nonDerivative · entry 1

RA CAPITAL MANAGEMENT, L.P. · CIK 0001346824 · 10% owner

RA Capital Healthcare Fund LP · CIK 0001315082 · 10% owner

Kolchinsky Peter · CIK 0001384859 · 10% owner

Shah Rajeev M. · CIK 0001619841 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 2,774,398

F2 · price: This transaction was executed in multiple trades at prices ranging from $3.35 to $3.48; the price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide full information regarding the number of shares and prices at which these transactions, and all other transactions reported in this Form 4, were effected upon request to the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.

F1 · balance_after: These securities include 2,774,398 held directly by RA Capital Healthcare Fund, L.P. (the "Fund").

F1 · ownership.nature: These securities include 2,774,398 held directly by RA Capital Healthcare Fund, L.P. (the "Fund").

F7 · ownership.nature: RA Capital Management, L.P. (the "Adviser") is the investment manager for the Fund. The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.

SEC source: 0001567619-22-013154 · doc1.xml · nonDerivative · entry 1

Leonard Braden Michael · CIK 0001373603 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · Holding of BML Investment Partners, L.P.

Disclosed balance after: 3,017,774

F2 · price: The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $1.06 to $1.13. Full information regarding the number of shares purchased at each separate price can be furnished to the SEC staff upon request.

F1 · ownership.nature: BML Capital Management, LLC ("BML Capital") serves as the general partner of BML Investment Partners, L.P., a Delaware limited partnership (the "Fund"), which is the direct owner of the subject shares. Mr. Leonard is the managing member of BML Capital, and exercises investment and voting control over the subject shares. Accordingly, shares owned directly by the Fund may be regarded as being beneficially owned by Mr. Leonard. Notwithstanding, Mr. Leonard disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein.